Akèy › Kansè lestomak › Oregon
Etid klinik pou Kansè lestomak nan Oregon
14 etid pou Kansè lestomak ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oncology Associates Of Oregon, Pc, Eugene
- Northwest Cancer Specialists, P.C., Portland
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07221149A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Oregon Health and Science University, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07700979Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Portland
- Research Site, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Providence Portland Medical Center, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06731478Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06974110A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.